Pfizer/GSK HIV Spin-Off ViiV Healthcare Debuts With Personalized Drugs in Portfolio | GenomeWeb

By Turna Ray

ViiV Healthcare, GlaxoSmithKline and Pfizer’s joint spin-off venture to market HIV treatments, will include in its pipeline at least two personalized drugs — Epizicom, which combines lamivudine and the genetically targeted abacavir, and the CCR5-antagonist Selzentry.

ViiV Healthcare, which GSK and Pfizer launched last week, is a new company combining the two firms’ HIV divisions and products. The companies first announced the decision to create the spin-off in April.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.